BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35468695)

  • 1. Targeted Therapy in the Management of Modern Craniopharyngiomas.
    Reyes M; Taghvaei M; Yu S; Sathe A; Collopy S; Prashant GN; Evans JJ; Karsy M
    Front Biosci (Landmark Ed); 2022 Apr; 27(4):136. PubMed ID: 35468695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives.
    Agosti E; Zeppieri M; Antonietti S; Piazza A; Ius T; Fontanella MM; Fiorindi A; Panciani PP
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.
    Prieto R; Pascual JM
    Pituitary; 2018 Aug; 21(4):431-442. PubMed ID: 29700680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Craniopharyngioma: a roadmap for scientific translation.
    Gupta S; Bi WL; Giantini Larsen A; Al-Abdulmohsen S; Abedalthagafi M; Dunn IF
    Neurosurg Focus; 2018 Jun; 44(6):E12. PubMed ID: 29852761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
    Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
    Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
    He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
    Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
    Gritsch D; Santagata S; Brastianos PK
    Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
    Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
    Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
    Erfurth EM
    J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
    Robinson LC; Santagata S; Hankinson TC
    Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
    Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
    Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.